OncoMatch/Clinical Trials/NCT06716164

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research

Is NCT06716164 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Metabolically Armed CD19 CAR-T cells for non-hodgkin lymphoma,b cell.

Early Phase 1RecruitingZhejiang UniversityNCT06716164Data as of May 2026

Treatment: Metabolically Armed CD19 CAR-T cells — A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Non-Hodgkin lymphoma

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Biomarker criteria

Required: CD19 positive expression (positive)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 2 prior lines

Must have received: CD20 antibody (rituximab)

treated with one standard treatment regimen and one salvage regimen treated with rituximab or another CD20 antibody drug and at least two treatment regiments appropriate for their disease, one of which should include anthracyclines

Must have received: anthracycline

at least two treatment regiments appropriate for their disease, one of which should include anthracyclines

Cannot have received: chemotherapy (other than preconditioning chemotherapy)

Patients who had received chemotherapy other than preconditioning chemotherapy within 2 weeks prior to Meta10-19 infusion

Lab requirements

Blood counts

Lymphocyte count ≥ 0.5×10^9/L (except for those receiving bridging chemotherapy); Platelet count ≥ 25×10^9/L; Hemoglobin ≥ 70.0 g/L

Kidney function

Serum creatinine (Scr) ≤ 1.5 x ULN, or endogenous creatinine clearance ≥ 40 mL/min (using Cockcroft-Gault formula)

Liver function

ALT ≤ 2.5 x ULN; AST ≤ 2.5 ×ULN; Total bilirubin (TBIL) ≤ 2 ×ULN; Subjects with total bilirubin < 3 × ULN and direct bilirubin < 1.5× ULN with Gilbert-Meulengracht syndrome could be included; ALP ≤ 2.5 ×ULN; In case of bone or liver metastasis, AST, ALT and ALP ≤ 5 ×ULN

Cardiac function

Hemodynamic stability determined by echocardiography or MUGA and LVEF ≥45%

Organ function: CBC, biochemistry, pulmonary function, cardiac function as specified

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify